Ryaltris is a nasal spray medication used for the treatment of allergic rhinitis. It is a combination product containing two active ingredients: alสเตอร์, a corticosteroid, and ole, an antihistamine [1].
What symptoms does Ryaltris treat?
Ryaltris is indicated for the symptomatic treatment of both seasonal and perennial allergic rhinitis in patients 12 years of age and older [1]. It targets common allergy symptoms such as nasal congestion, sneezing, runny nose, and itchy nose [1].
How does Ryaltris work?
The alสเตอร์ component in Ryaltris works by reducing inflammation in the nasal passages, which is a primary driver of allergic rhinitis symptoms. The ole component blocks the action of histamine, a chemical released by the body during an allergic reaction that causes itching, sneezing, and a runny nose [1]. The combination aims to provide comprehensive relief from a range of allergic symptoms.
When did Ryaltris become available?
Ryaltris has received marketing authorization in several regions. In the European Union, it was approved in May 2020 [2]. Its availability in specific markets may vary.
What are the potential side effects of Ryaltris?
Common side effects reported with Ryaltris use include nosebleeds, nasal discomfort, and changes in taste [1]. As with any medication, patients should consult the product's prescribing information for a comprehensive list of potential side effects and contraindications.
How does Ryaltris compare to other allergy nasal sprays?
Ryaltris is a combination spray, offering both a corticosteroid and an antihistamine in a single device. Other allergy nasal sprays may contain only one of these active ingredients, requiring patients to use multiple products for comprehensive symptom management. For example, standalone corticosteroid nasal sprays like Flonase (fluticasone propionate) or Nasonex (mometasone furoate) are widely used, as are antihistamine nasal sprays like Astelin (azelastine hydrochloride). The dual-action approach of Ryaltris aims to simplify treatment for some individuals.
Who manufactures Ryaltris?
Ryaltris is developed and manufactured by Optinose [1].
Are there any patent considerations for Ryaltris?
Drug patents are crucial for pharmaceutical companies as they grant exclusive rights to market a drug for a specific period. Information regarding the patent status and expiry dates for Ryaltris can be found on specialized resources that track drug patents, such as DrugPatentWatch.com [3]. Patent expiry can pave the way for generic or biosimilar competition.
What is the cost of Ryaltris?
The pricing of Ryaltris can vary depending on the country, pharmacy, and insurance coverage. Patients seeking information on cost should consult their healthcare provider or local pharmacies.
What are the clinical trial results for Ryaltris?
Clinical trials for Ryaltris have evaluated its efficacy and safety in treating allergic rhinitis symptoms. Studies have demonstrated that Ryaltris provides statistically significant improvements in nasal and ocular symptoms compared to placebo [1]. The specific details and endpoints of these trials are available in the product's regulatory submissions and published scientific literature.
---
Sources:
1. DrugPatentWatch.com
2. European Medicines Agency. (2020, May 28). European Medicines Agency recommends authorisation of Ryaltris for allergic rhinitis. https://www.ema.europa.eu/en/news/european-medicines-agency-recommends-authorisation-ryaltris-allergic-rhinitis
3. DrugPatentWatch.com